Boston Clinical Trials LLC

1. Eli Lilly and Company $1,349,160 38 payments
2. Biohaven Pharmaceuticals, Inc. $755,793 28 payments
3. Allergan Inc. $581,374 37 payments
4. ITI, Inc. $478,557 57 payments
5. Sumitomo Pharma America, Inc. $389,341 67 payments
6. AbbVie, Inc. $280,166 63 payments
7. Sanofi Pasteur Inc. $184,512 13 payments
8. Biohaven Pharmaceutical Holding Company Ltd. $172,610 29 payments
9. F. Hoffmann-La Roche AG $133,172 43 payments
10. Supernus Pharmaceuticals, Inc. $109,342 24 payments

1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $430,387 14 payments
2. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $398,227 15 payments
3. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $376,642 15 payments
4. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $270,917 6 payments
5. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $217,660 22 payments
6. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $191,078 48 payments
7. A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older $184,512 13 payments
8. An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $172,910 25 payments
9. A Phase 4 Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $162,879 2 payments
10. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (Oab) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $162,167 6 payments

1. Patient care $83,410 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.